Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-17
DOI
10.3389/fendo.2021.774686
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current FDA-Approved Therapies for High-Grade Malignant Gliomas
- (2021) Jacob P. Fisher et al. Biomedicines
- Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis
- (2021) Mei Luo et al. Frontiers in Neurology
- Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas
- (2021) Ashutosh Rai et al. Frontiers in Endocrinology
- Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas—A German Survey
- (2020) Ulf Elbelt et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature
- (2020) E. Guadagno et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Endonasal endoscopic versus microscopic transsphenoidal surgery in pituitary tumors among the young: A comparative study & meta-analysis
- (2020) Sivashanmugam Dhandapani et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Bevacizumab in Aggressive Pituitary Adenomas – Experience with 3 Patients
- (2020) Katharina Osterhage et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas
- (2019) Rovshan Hasanov et al. ENDOCRINE PATHOLOGY
- Surgery, octreotide, temozolomide, bevacizumab, radiotherapy and pegvisomant treatment of an AIP mutation positive child
- (2019) Pinaki Dutta et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment and long-term outcomes in pituitary carcinoma: a cohort study
- (2019) Fernando Santos-Pinheiro et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study
- (2019) Haihui Jiang et al. JOURNAL OF NEURO-ONCOLOGY
- How and when to use temozolomide to treat aggressive pituitary tumours
- (2019) Ben C Whitelaw ENDOCRINE-RELATED CANCER
- Definition and diagnosis of aggressive pituitary tumors
- (2019) Leandro Kasuki et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review
- (2019) Simona Serioli et al. Cancers
- Aggressive and malignant pituitary tumours: state-of-the-art
- (2018) Dorota Dworakowska et al. ENDOCRINE-RELATED CANCER
- Aggressive pituitary tumours and carcinomas: two sides of the same coin?
- (2018) Jacqueline Trouillas et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Early recognition and initiation of temozolomide chemotherapy for refractory, invasive pituitary macroprolactinoma with long-term sustained remission: a case report
- (2018) Garni Barkhoudarian et al. World Neurosurgery
- Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
- (2018) Luis V. Syro et al. Frontiers in Endocrinology
- Imatinib Inhibits GH Secretion From Somatotropinomas
- (2018) Prakamya Gupta et al. Frontiers in Endocrinology
- Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
- (2017) Hélène Lasolle et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment of aggressive prolactinoma with temozolomide
- (2017) Cheng Chen et al. MEDICINE
- Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect
- (2017) Pinaki Dutta et al. World Neurosurgery
- MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
- (2016) J Cros et al. ENDOCRINE-RELATED CANCER
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
- (2015) Marco Losa et al. JOURNAL OF NEURO-ONCOLOGY
- The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy
- (2014) Youwei Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
- (2008) Ann I. McCormack et al. CLINICAL ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation